Market Dynamics and Financial Trajectory for Pregnyl (Human Chorionic Gonadotropin)
Overview of Pregnyl
Pregnyl, a brand of human chorionic gonadotropin (hCG), is a biologic drug used in various medical treatments, including female infertility, male hypogonadism, and ovulation induction. Understanding the market dynamics and financial trajectory of Pregnyl is crucial for stakeholders in the pharmaceutical and healthcare industries.
Market Size and Growth
The global human chorionic gonadotropin (hCG) market, which includes Pregnyl, has been experiencing significant growth. In 2017, the market generated a revenue of $688 million and is projected to reach $1,239 million by 2025, registering a substantial increase[1].
Compound Annual Growth Rate (CAGR)
The hCG market is expected to register a CAGR of nearly 7.6% over the forecast period. This growth is driven by increasing demand for infertility treatments and the expanding product portfolio of key players in the industry[4].
Key Market Drivers
Increasing Prevalence of Infertility
The growing burden of infertility, particularly in regions like North America, is a significant driver for the hCG market. According to the CDC, about 1 in 5 women aged 15-49 years with no prior births are unable to get pregnant after one year of trying, and 1 in 4 women in this group have difficulty getting pregnant or carrying a pregnancy to term[4].
Advanced Healthcare Infrastructure
Well-established healthcare infrastructure and favorable reimbursement policies in regions like North America contribute to the market's growth. These factors ensure better access to hCG treatments, boosting demand[4].
Strong Distribution Networks and R&D Investments
Key players in the hCG market have maintained their market position through strong distribution networks and significant investments in research and development. This has led to a vast product portfolio available in different strengths, catering to various treatment needs[1].
Impact of COVID-19
The COVID-19 pandemic had a negative impact on the hCG market due to reduced foot traffic in hospitals and clinics, as well as fear of infection among patients and physicians. However, with ongoing vaccinations and decreasing COVID-19 cases, the market is expected to regain normalcy over the coming years[4].
Financial Aspects
Pricing and Cost
The cost for Pregnyl 10,000 units intramuscular powder for injection is around $132 for a supply of one powder for injection, depending on the pharmacy. Generic versions of hCG are also available, with prices ranging from $131.92 to $197.29 for a single powder for injection[5].
Revenue Projections
Given the projected market size of $1,239 million by 2025 for the global hCG market, Pregnyl, as a prominent brand, is expected to contribute significantly to this revenue. The market's growth trajectory suggests that Pregnyl will continue to be a lucrative product in the biologic drug segment.
Competitive Landscape
Key Players
The hCG market is dominated by key players who have expanded their product portfolios through acquisitions. For instance, Pregnyl was originally manufactured by Organon Ltd. and later acquired by Merck. These strategic moves have helped these companies maintain their market position and drive growth[1].
Distribution and Access
Comprehensive Coverage and Support
Programs like Progyny, which offer comprehensive fertility treatment coverage, including hCG medications, enhance access to these treatments. Such programs provide personalized support, education, and referral services, ensuring equitable and inclusive access to fertility care[2].
Regulatory and Technological Trends
Biologic Therapeutic Drugs Market
The broader biologic therapeutic drugs market, which includes hCG, is expected to grow from $452.9 billion in 2023 to $823.4 billion by 2028, with a CAGR of 12.7%. This growth is driven by advancements in biologic manufacturing, including cell and gene therapy, and the increasing use of biologics to treat various diseases[3].
Regional Market Analysis
North America
North America is anticipated to dominate the hCG market over the forecast period due to its well-established healthcare infrastructure and favorable reimbursement policies. The region's high prevalence of infertility also contributes to the market's growth[4].
Patient Assistance and Discounts
Discount Programs
To make Pregnyl more accessible, various discount programs and patient assistance plans are available. For example, the Drugs.com Discount Card can save patients up to 80% on prescription medicines, including Pregnyl[5].
Key Takeaways
- The global hCG market, including Pregnyl, is projected to reach $1,239 million by 2025.
- The market is driven by increasing infertility rates, advanced healthcare infrastructure, and strong distribution networks.
- The COVID-19 pandemic had a temporary negative impact, but the market is expected to recover.
- Pregnyl's pricing varies, with generic options available, and the drug is covered under comprehensive fertility treatment programs.
- North America is expected to dominate the market due to favorable reimbursement policies and high infertility rates.
FAQs
What is the current market size of the human chorionic gonadotropin (hCG) market?
The global hCG market generated a revenue of $688 million in 2017 and is expected to reach $1,239 million by 2025[1].
How has the COVID-19 pandemic affected the hCG market?
The pandemic led to a decline in ART cycles due to local restrictions and fear of infection, but the market is expected to regain normalcy as COVID-19 cases decrease[4].
What are the key drivers of the hCG market?
Key drivers include the increasing prevalence of infertility, advanced healthcare infrastructure, and strong distribution networks along with significant R&D investments[1][4].
Is Pregnyl covered under any comprehensive fertility treatment programs?
Yes, Pregnyl is covered under programs like Progyny, which offer comprehensive fertility treatment coverage, including medication and other services[2].
How much does Pregnyl cost?
The cost for Pregnyl 10,000 units intramuscular powder for injection is around $132 for a supply of one powder for injection, depending on the pharmacy[5].
Sources
- Allied Market Research - Human Chorionic Gonadotropin (HCG) Market
- Yale University - Your Progyny Benefit - It's Your Yale
- BCC Research - Big Growth Ahead Biologic Drugs Market to Hit 823.4 Billion by 2028
- Mordor Intelligence - Human Chorionic Gonadotropin Market Size & Share Analysis
- Drugs.com - Pregnyl Prices, Coupons, Copay Cards & Patient Assistance
